Systematic reviews are of great importance in the current era of evidence-based medicine. They provide transparent and reproducible insight into the available scientific evidence for a specific question and the possible lack thereof. Systematic reviews form the basis for evidence-based guidelines, which are essential for the translation of scientific evidence into clinical practice. In this way, the care and thus the health of children with cancer and survivors can be optimized.
My main objective in the Princess Máxima Center for pediatric oncology is to perform and provide methodological support for (Cochrane) systematic reviews in the field of pediatric oncology and survivorship care. Furthermore I’m involved in methodological research in the field of systematic reviews and provide education. I’m also involved in the preparation of evidence-based guidelines.
Besides systematic reviews and guidelines, I’m also involved in research into the late effects of childhood cancer treatment, especially cardiac late effects, both nationally and internationally, for example within the LATER CARD consortium and the European PanCareSurFup study.
Supervisor: Prof. Dr. Leontien Kremer
Mulder RL, Bresters D, Van den Hof M, Koot BG, Castellino SM, Loke YKK, Post PN, Postma A, Szőnyi LP, Levitt GA, Bardi E, Skinner R, van Dalen EC. Hepatic late adverse effects after antineoplastic treatment for childhood cancer. Cochrane Database Syst Rev. 2019;4(4):CD008205.
Armenian SH, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, Ky B, Moslehi J, Mulrooney DA, Nathan PC, Ryan TD, van der Pal HJ, van Dalen EC, Kremer LCM. Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention. J Clin Oncol. 2018;36(21):2135-2144.
Skoetz N, Goldkuhle M, Weigl A, Dwan K, Labonté V, Dahm P, Meerpohl JJ, Djulbegovic B, van Dalen EC. Methodological review showed correct absolute effect size estimates for time-to-event outcomes in less than one-third of cancer-related systematic reviews. J Clin Epidemiol. 2019;108:1-9.
De Baat EC, van Dalen EC, Mulder RL, Hudson MM, Ehrhardt MJ, Engels FK, Feijen EAM, Grotenhuis HB, Leerink JM, Kapusta L, Kaspers GJL, Merkx R, Mertens L, Skinner R, Tissing WJE, de Vathaire F, Nathan PC, Kremer LCM, Mavinkurve-Groothuis AMC, Armenian S. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Child Adolesc Health. 2022 Dec;6(12):885-894. doi: 10.1016/S2352-4642(22)00239-5. Epub 2022 Sep 27. PMID: 36174614.
De Baat EC, Feijen EAM, Reulen RC, Allodji RS, Bagnasco F, Bardi E, Belle FN, Byrne J, van Dalen EC, Debiche G, Diallo I, Grabow D, Hjorth L, Jankovic M, Kuehni CE, Levitt G, Llanas D, Loonen J, Zaletel LZ, Maule MM, Miligi L, van der Pal HJH, Ronckers CM, Sacerdote C, Skinner R, Jakab Z, Veres C, Haddy N, Winter DL, de Vathaire F, Hawkins MM, Kremer LCM. Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors: A PanCareSurFup and ProCardio Cohort and Nested Case-Control Study. J Clin Oncol. 2022:JCO2102944.